Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles ...
NNNN is currently pivoting from pandemic tests and expanding its assays into oncology, cardiovascular, hormonal, and infectious diseases. Their 2024 revenues increased YoY with gross margin improving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback